Pernix 500K Warrants, Exercise Price $4.28; Total Gain Today for POZN $2+ million, will increase to $5-6 million;
Altough POZN already soldout its Treximet royalty rights to a financial investor, todays deal is a substantial windfall profit for POZN.
- Pernix lifted its 2015 forecast to $220 million and EbitA to $95 million. This should bring Pernix share price up to $15 (less than 3 times revenue) and at low EPS multiple
- At $15 per share the exercised warrants make an extraordinary profit at POZN of $ 5 million
- The exUS treximet rights for all dose strengths are again open for licencing for POZN - this is a big asset. Pernix payed more than $200 million to GSK for the US rights just now - this gives a clue about the deal value possible for POZN with EU and ROW rights!